Abstract: Disclosed are a construction method of a recombinant drug-resistant Mycobacterium bovis (M. bovis) Bacillus Calmette-Guerin (BCG) strain and a pharmaceutical composition for treating tuberculosis (TB). The construction method includes: using BCG as an original bacterial strain to construct a drug-resistant BCG strain resistant to at least one selected from the group consisting of STR, LFX, EMB, PRO, PAS, and AMK; and further inserting sequence fragments that can express related antigens Ag85b and Rv2628 causing an immune response into a genome of the strain to construct a recombinant drug-resistant BCG strain. The recombinant drug-resistant BCG strain can compete with Mycobacterium tuberculosis (Mtb) for growth, thereby accelerating the death of Mtb. When used in combination with a drug for treating TB, the recombinant drug-resistant BCG strain can further enhance a therapeutic effect for Mtb, and can also avoid re-infection of a patient.